ArticleFrontiers in digital health2026
Radiomics-Based prediction of renal prognosis in ANCA-associated vasculitis.
Article in Frontiers in digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and validate a non-invasive prediction model combining renal CT radiomics features and clinical markers for assessing long-term renal prognosis at 1, 3, and 5 years in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Methods: A retrospective cohort of 262 AAV patients from Peking Union Medical College Hospital (2015-2020) was analyzed. Radiomics features (morphological, first-order, and texture) were extracted from segmented renal parenchyma on abdominopelvic CT. Clinical markers included demographics, serum creatinine, complement component 3 (C3), and other laboratory indicators. Renal volume, serum creatinine, and complement component 3 (C3) were pre-specified as predictors based on Results: The mean follow-up was 40.8 months; 59 patients (23%) developed ESRD (56 within 3 years) and 29 (11%) died. The combined model (renal volume + sCr + C3) achieved an AUC of 0.93 for 3-year ESRD prediction (clinical-only model: 0.91), with renal volume independently associated with ESRD (Wald Conclusion: The integrated radiomics-clinical model provides accurate, non-invasive risk stratification for long-term renal outcomes in AAV, facilitating personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.